Company Description
Aclarion, Inc. operates as a healthcare technology company in the United States.
The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments.
It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine.
The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface.
In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient.
The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021.
Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
| Country | United States |
| Founded | 2008 |
| IPO Date | Apr 22, 2022 |
| Industry | Health Information Services |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Brent Ness |
Contact Details
Address: 8181 Arista Place, Suite 100 Broomfield, Colorado 80021 United States | |
| Phone | 833 275 2266 |
| Website | aclarion.com |
Stock Details
| Ticker Symbol | ACON |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.35 |
| CIK Code | 0001635077 |
| CUSIP Number | 655187409 |
| ISIN Number | US6551872012 |
| Employer ID | 47-3324725 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Brent Ness | Chief Executive Officer, President and Director |
| Dr. Jeffrey John Thramann M.D. | Executive Chairman |
| John Lorbiecki | Chief Financial Officer |
| Ryan Bond | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | 10-Q | Quarterly Report |
| Jul 21, 2025 | 8-K | Current Report |
| Jul 7, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jul 7, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | DEF 14A | Other definitive proxy statements |
| May 5, 2025 | EFFECT | Notice of Effectiveness |
| May 2, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 29, 2025 | UPLOAD | Filing |